GO
Loading...

Celgene Corp

More

  • Early Glance: Biotechnology companies Thursday, 11 Dec 2014 | 11:28 AM ET

    Amgen Inc. rose $2.53 or 1.5 percent, to $167.92. Biogen Idec rose $2.90 or. 8 percent, to $346.49. Celgene Corp. rose $1.91 or 1.7 percent, to $117.55.

  • Final Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 6:09 PM ET

    Amgen Inc. fell $4.00 or 2.4 percent, to $165.39. Biogen Idec fell $4.02 or 1.2 percent, to $343.59. Celgene Corp. fell $3.04 or 2.6 percent, to $115.64.

  • Midday Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 1:18 PM ET

    Amgen Inc. fell $1.19 or. 7 percent, to $168.20. Biogen Idec fell $1.82 or. 5 percent, to $345.79. Celgene Corp. fell$. 97 or. 8 percent, to $117.71.

  • Early Glance: Biotechnology companies Wednesday, 10 Dec 2014 | 10:41 AM ET

    Amgen Inc. rose$. 07 or percent, to $169.46. Biogen Idec fell$. 17 or percent, to $347.44. Celgene Corp. fell$. 39 or. 3 percent, to $118.29.

  • Final Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 6:10 PM ET

    Amgen Inc. fell $2.25 or 1.3 percent, to $169.39. Biogen Idec rose $3.56 or 1.0 percent, to $347.61. Celgene Corp. rose$. 49 or. 4 percent, to $118.68.

  • Midday Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 1:21 PM ET

    Amgen Inc. fell $2.16 or 1.3 percent, to $169.48. Biogen Idec fell$. 23 or. 1 percent, to $343.82. Celgene Corp. rose$. 35 or. 3 percent, to $118.54.

  • This data represents a "quantum leap" in the management of this disorder by shifting from "life-long symptom management to once-and-done cures," Roth Capital Partner's Debjit Chattopadhyay said, raising his price target on the stock to $90 from $50. LentiGlobin's results read-through favorably to the sickle-cell indication, Piper Jaffray analysts said,...

  • Early Glance: Biotechnology companies Tuesday, 9 Dec 2014 | 10:21 AM ET

    Amgen Inc. fell $2.53 or 1.5 percent, to $169.11. Biogen Idec fell $2.51 or. 7 percent, to $341.54. Celgene Corp. fell $1.02 or. 9 percent, to $117.17.

  • ASH: The Celgene show, this time through partners Monday, 8 Dec 2014 | 1:33 PM ET

    Celgene's partnering strategy, which has accelerated in recent years, is starting to bear fruit; many of the most-watched stocks out of ASH fall under its umbrella.

  • Midday movers: McDonald's, Sony, Celgene & more Monday, 8 Dec 2014 | 1:12 PM ET

    Some of Monday's midday movers:

  • Celgene CEO: Cancer drug pipeline booming  Monday, 8 Dec 2014 | 12:37 PM ET

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.

  • Lightning Round: Time to buy buy buy for 2015 Thursday, 4 Dec 2014 | 6:50 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer’s big discovery under the market's hood Wednesday, 3 Dec 2014 | 6:16 PM ET

    Jim Cramer takes a close look under the market's hood and makes a big discovery that could impact your portfolio.

  • Cramer's heated love affair with biotech Tuesday, 2 Dec 2014 | 6:33 PM ET
    File photo: Michael LeClair, left, and Kevin Fleurimond, in the manufacturing room of Biogen Idec.

    As the global economy faces headwinds each day, Jim Cramer knows this group can withstand stormy weather more often than the rest.

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record, healthcare leads gains Tuesday, 18 Nov 2014 | 1:45 PM ET

    Actavis Plc, Gilead, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.4 percent, while shares of Actavis were up 7.7 percent, Gilead's rose 2.9 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • Midday movers: FibroGen, Google, McDonald's & more Friday, 14 Nov 2014 | 1:12 PM ET

    Some of Friday's midday movers:

  • Cramer spotlight: These three sectors keep growing Tuesday, 11 Nov 2014 | 6:05 PM ET
    Traders on the floor of the New York Stock Exchange.

    Think that the market was uneventful on Tuesday? Not so fast, Jim Cramer sees these three sectors growing fast, which could lead to profits.

  • Cramer's military salute: Long-term investing keys Monday, 10 Nov 2014 | 6:10 PM ET

    Jim Cramer focuses on three long-term investment themes specialized for veterans and active-duty soldiers.